How much revenue does PsyBio Therapeutics make?

PsyBio Therapeutics reported $0 in revenue for fiscal year 2022. In Q2 2023 revenue was $0.

What companies are similar to PsyBio Therapeutics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Wildflower Brands Inc. (WLDFF), Evolutionary Genomics, Inc. (FNAM), Speakeasy Cannabis Club Ltd. (SPBBF), RavenQuest BioMed Inc. (RVVQF).

PsyBio Therapeutics Corp. (PSYBF) Stock

About PsyBio Therapeutics Corp.

PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company was incorporated ...

At a glance

PsyBio Therapeutics reported revenue of $0 for fiscal year 2022, and net income of -$4.89 million. In Q2 2023 (the quarter ended June 30, 2023) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2022.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.